A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
Negative Impact of Rumors on Kostaive Is Immense: Meiji Pharma President
The uptake of Meiji Seika Pharma’s COVID-19 vaccine Kostaive is significantly affected by what is seen as unscientific information swirling around among a certain community of people, the company’s president Daikichiro Kobayashi said on October 8. The self-amplifying mRNA jab…
To read the full story
Related Article
- Meiji Pharma Sues CDP Lawmaker for Defamation over Kostaive
December 26, 2024
- Meiji Seika Pharma “Preparing” to Sue CDP’s Haraguchi
November 5, 2024
- Academic Societies Urge COVID-19 Vaccinations, Deny Kostaive “Shedding”
October 22, 2024
- Ex-Health Minister Gets Kostaive Shot, Warns against “Unscientific Concerns”
October 21, 2024
- Meiji’s COVID Jab Might Miss Initial Plan, but Awaits Real Game Next Year
September 26, 2024
BUSINESS
- Renascience to Open Branch Lab of Northwestern University Longevity Institute
January 23, 2025
- Shionogi Partners with Hitachi to Provide Digital Services
January 23, 2025
- Alimta Generics Broaden Label for Keytruda Combination in Japan
January 23, 2025
- Shionogi Wins Stockpile Pact for Xocova in Taiwan, NDA Accepted for Review
January 23, 2025
- Daiichi Sankyo Sets Up Advanced Drug-Discovery Lab in San Diego
January 22, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…